Related Experiment Video

Updated: Nov 21, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.3K

Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment

Eduardo Chuquiure-Valenzuela1, Patricia Chuquiure-Valenzuela2, María J Chuquiure-Gil3

  • 1Department of Clinical Cardiology, National Institute Cardiology Ignacio Chávez, Mexico City, Mexico.

Archivos De Cardiologia De Mexico
|January 18, 2021
PubMed

Insights

Severe coronavirus disease (COVID)-19 can cause myocardial injury and worsen cardiovascular conditions. This review guides safe treatment by examining adverse effects and drug interactions in COVID-19 patients with heart disease.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Severe coronavirus disease (COVID)-19 is linked to significant systemic inflammation.
  • This inflammation can lead to myocardial injury, including acute myocarditis, inflammation, and necrosis.
  • These cardiac issues can exacerbate existing cardiovascular conditions like heart failure and hypertension, leading to poor outcomes.

Purpose of the Study:

  • To provide guidance on managing cardiovascular (CV) drugs in COVID-19 patients.
  • To correlate adverse effects and pharmacological interactions of CV drugs used in COVID-19 treatment.
  • To offer a synopsis for safe and effective treatment strategies.

Main Methods:

  • Literature review and synthesis of existing data.
  • Analysis of pharmacological interactions between COVID-19 treatments and cardiovascular drugs.
  • Correlation of adverse effects with specific drug combinations.

Main Results:

  • COVID-19 treatments can interact with various cardiovascular medications.
  • Adverse effects on the cardiovascular system are a significant concern in severe COVID-19.
  • Understanding these interactions is crucial for patient outcomes.

Conclusions:

  • A comprehensive understanding of drug interactions is essential for managing COVID-19 patients with cardiovascular disease.
  • Guidance is needed to optimize treatment by minimizing adverse effects and drug interactions.
  • This synopsis aims to support clinicians in making informed therapeutic decisions.

Keywords:
Cardiovascular drugsPharmacology interactionsAdverse effectsCOVID-19

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
79
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
128
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
562
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
935